MCTL THERAPY FOR
COLORECTAL CANCER
An investigational cell-based immunotherapy being explored for advanced CRC β including MSS tumors that do not respond to checkpoint inhibitors. Understanding eligibility, rationale, and realistic expectations.
analyticsAt a Glance
- check_circleInvestigational β explored at select Chinese centres
- check_circleRelevant for MSS CRC and checkpoint inhibitor-resistant disease
- check_circleTargets multiple tumor-associated antigens simultaneously
- check_circleSuitability requires full specialist medical review
Why Colorectal Cancer Is Challenging for Immunotherapy
Approximately 85% of colorectal cancers are microsatellite stable (MSS) β a subtype that historically responds poorly to checkpoint inhibitors, the backbone of modern immunotherapy.
The MSS Problem
MSS tumors have low mutation burden and fewer neoantigens β meaning fewer signals for the immune system to recognise. PD-1 inhibitors, effective in MSI-high disease, have minimal benefit in MSS CRC.
Why Multi-Target May Help
By training T cells against several tumor-associated antigens simultaneously (rather than relying on neoantigen recognition), MCTL attempts to overcome the low immunogenicity characteristic of MSS disease.
Who This May Be Relevant For
MCTL review may be relevant for patients in specific situations β eligibility cannot be assumed from diagnosis alone.
Stage IV / Metastatic CRC
Progressed after FOLFOX, FOLFIRI, capecitabine-based regimens, and targeted therapies (bevacizumab, cetuximab, or regorafenib).
MSS Tumors Not Responding to Immunotherapy
The ~85% of CRC patients with MSS disease who are ineligible for or have not responded to checkpoint inhibitors.
MSI-High CRC Progressed Despite Checkpoint Inhibitors
Patients who initially qualified for immunotherapy but have since progressed on PD-1/PD-L1 therapy.
Potential Benefits vs Limitations in CRC
Rationale
- Multi-antigen targetingAddresses the lack of single dominant target in CRC
- Does not depend on PD-L1 expressionMay have rationale even in immunologically cold tumors
- Can be combined with checkpoint blockadeToripalimab combination explored in some protocols
Limitations
- Limited CRC-specific published dataMost published MCTL data is in NSCLC and pancreatic cancer
- Immunosuppressive tumor microenvironmentCRC often has strong local immune suppression that may limit T-cell activity
- Still investigationalNo large randomised trial evidence in CRC specifically
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Options for Advanced Colorectal Cancer?
CancerFax reviews your full medical file β including MSS/MSI status, prior treatment history, and biomarker profile β to help you understand whether MCTL or another advanced therapy is a realistic next step.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.